Viking Global Investors LP decreased its holdings in shares of AnaptysBio Inc (NASDAQ:ANAB) by 3.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 799,897 shares of the biotechnology company’s stock after selling 30,263 shares during the quarter. Viking Global Investors LP’s holdings in AnaptysBio were worth $45,130,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ANAB. Bank of America Corp DE boosted its holdings in AnaptysBio by 141.2% during the fourth quarter. Bank of America Corp DE now owns 4,397 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 15,067 shares during the last quarter. Geode Capital Management LLC raised its position in AnaptysBio by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 253,758 shares of the biotechnology company’s stock worth $16,187,000 after acquiring an additional 18,769 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in AnaptysBio during the first quarter worth $290,000. State Board of Administration of Florida Retirement System raised its position in AnaptysBio by 1.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 10,147 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 140 shares in the last quarter. Finally, TD Asset Management Inc. raised its position in AnaptysBio by 45.4% during the first quarter. TD Asset Management Inc. now owns 20,509 shares of the biotechnology company’s stock worth $1,498,000 after acquiring an additional 6,400 shares in the last quarter.

Several analysts have issued reports on ANAB shares. ValuEngine raised shares of AnaptysBio from a “hold” rating to a “buy” rating in a research report on Friday, August 16th. Stifel Nicolaus set a $63.00 price target on shares of AnaptysBio and gave the stock a “hold” rating in a research report on Monday, August 12th. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th. SunTrust Banks dropped their price target on shares of AnaptysBio from $125.00 to $93.00 and set a “buy” rating on the stock in a research report on Monday, June 24th. Finally, Credit Suisse Group dropped their price target on shares of AnaptysBio from $79.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. AnaptysBio currently has an average rating of “Buy” and a consensus target price of $106.89.

Shares of ANAB traded down $2.00 during trading hours on Wednesday, hitting $42.73. The company had a trading volume of 8,495 shares, compared to its average volume of 286,776. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -17.12 and a beta of 1.55. The business has a fifty day moving average of $46.05 and a 200-day moving average of $62.80. AnaptysBio Inc has a 12 month low of $38.53 and a 12 month high of $110.00.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.97) by $0.08. The company had revenue of $5.00 million during the quarter. AnaptysBio’s revenue for the quarter was up 4900.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.57) earnings per share. On average, sell-side analysts forecast that AnaptysBio Inc will post -4.13 earnings per share for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Story: Why do corrections happen?

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.